Results 71 to 80 of about 626,377 (227)

PCSK9 inhibitors – past, present and future [PDF]

Expert Opinion on Drug Metabolism & Toxicology, 2015
Lowering low-density lipoprotein cholesterol (LDL-C) reduces cardiovascular disease (CVD) morbidity and mortality. Statins are the treatment of choice for lowering LDL-C but a considerable number of patients treated with statins are unable to achieve LDL-C target values and many are statin-intolerant.
openaire   +2 more sources

Association between PCSK9 inhibitors and acute kidney injury: a pharmacovigilance study

Frontiers in Pharmacology
BackgroundPCSK9 inhibitors are a novel class of lipid-lowering medications, and numerous clinical studies have confirmed their significant role in improving the progression of chronic kidney disease.
Hailing Liu
doaj   +1 more source

Cardiovascular and neuropsychiatric outcomes with PCSK9 inhibitors in atherosclerotic cardiovascular disease: A retrospective cohort study

British Journal of Clinical Pharmacology, EarlyView.
Study design and main findings. After 1:1 propensity score matching, 60 885 PCSK9 inhibitor users and 60 885 statin‐only users with ASCVD were compared. Kaplan–Meier curves show 12‐month cumulative event‐free survival for MACE, psychiatric disease, and neurodegenerative disease.
Tianshu Gu, Yang Chen, Nan Zhang, Uazman Alam, Riccardo Proietti, Tong Liu, Kang‐Yin Chen, Gregory Y. H. Lip   +7 more
wiley   +1 more source

The Anti-Thrombotic Effects of PCSK9 Inhibitors

, 2023
Atherosclerosis is the primary process that underlies cardiovascular disease. The connection between LDL cholesterol and the formation of atherosclerotic plaques is established by solid evidence.
Tomáš Bolek, Jakub Benko, Marek Samec, Matej Samoš, Peter Galajda, Marián Mokáň, Martin Péč, Monika Péčová, Martin Jozef Péč, Jakub Jurica, Tatiana Hurtová   +10 more
core   +1 more source

PCSK9 peptide inhibitors [PDF]

Science-Business eXchange, 2014
Although many companies are chasing inhibitors of PCSK9 for lowering LDL cholesterol, antibodies or siRNAs that require injection are dominating the field. Roche's Genentech unit and a joint team from Pfizer and the University of Queensland are betting that peptides might provide an oral competitor.
openaire   +1 more source

Hybrid Macrocyclic Peptides — Synthetic Strategies to Diversify and Cyclize Peptide Libraries in Phage Display Selections

Chemistry – A European Journal, EarlyView.
Hybrid macrocyclic peptides unite genetically encoded peptide libraries with the structural complexity of synthetic small molecules. This Review critically analyzes phage‐compatible cyclization and diversification chemistries, highlights emerging opportunities beyond traditional cysteine‐based approaches, and outlines how future advances may enable the
Titia Rixt Oppewal, Clemens Mayer
wiley   +1 more source

Inhibiteurs de la PCSK9 : un nouveau traitement pour l’hypercholestérolémie [PDF]

, 2016
The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors appear to represent an important development in the management of hypercholesterolemia. US Food and Drug Administration and European Medicines Agency approved alirocumab and evolocumab,
Gencer, Baris, Rodondi, Nicolas, Mach, François   +2 more
core  

Application of PCSK9 Inhibitors in Practice [PDF]

Circulation Research, 2017
Although the discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) and development of therapeutic antagonists represent a major triumph of modern clinical medicine, efforts to implement PCSK9 inhibitors (PCSK9i) in patient care have been sobering.
Tina M, Kaufman, P Barton, Duell, Jonathan Q, Purnell, Cezary, Wójcik, Sergio, Fazio, Michael D, Shapiro   +5 more
openaire   +2 more sources

Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis

BMC Cardiovascular Disorders
Background High-intensity statin therapy is currently recommended initial guideline therapy in ACS treatment. However, only a minority of patients are achieving LDL-C attainment goal at 6 months.
Kaveh Hosseini, Hamidreza Soleimani, Saba Maleki, Amir Nasrollahizadeh, Sima Tayebi, John Nelson, Sean P. Heffron   +6 more
doaj   +1 more source

Early PCSK9 Inhibitor Use Correlates With Improved Outcomes in Patients With Acute Stroke Receiving Endovascular Therapy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background The clinical benefits of early PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor use in patients with acute large vessel occlusion undergoing endovascular therapy (EVT) remain unclear.
Tong Wu, Xiaolin Zhao, Mengxuan Xiao, Junlin Deng, Ziyu Chen, Daihong Cheng, Suyue Pan, Xianghong Liu, Yongming Wu, Kaibin Huang   +9 more
doaj   +1 more source